Filter Results:
(4,673)
Show Results For
- All HBS Web
(4,673)
- People (16)
- News (1,854)
- Research (2,239)
- Events (2)
- Multimedia (213)
- Faculty Publications (1,819)
Show Results For
- All HBS Web
(4,673)
- People (16)
- News (1,854)
- Research (2,239)
- Events (2)
- Multimedia (213)
- Faculty Publications (1,819)
- 02 Sep 2020
- News
How to Launch a New Biosciences Product: Start Small or Dive in?
- January 2023
- Case
Cleave Therapeutics: Taking a Risk on Oncology Drug Discovery
By: Regina Herzlinger and Brian Walker
What should a successful executive (HBS Baker Scholar) assess as her next move as the CEO of a firm with a promising and yet uncertain new drug? Amy Burroughs’ mandate to successfully commercialize Cleave Therapeutics’ drug for a cancer with no current successful... View Details
Keywords: Product Development; Leadership; Health Testing and Trials; Research and Development; Risk and Uncertainty; Financial Condition; Partners and Partnerships; Pharmaceutical Industry
Herzlinger, Regina, and Brian Walker. "Cleave Therapeutics: Taking a Risk on Oncology Drug Discovery." Harvard Business School Case 323-045, January 2023.
- Program
Succeeding as a Strategic CFO
decision-making skills Review and practice applying frameworks and tools of value-based management Learn about financial policies and practices used by other organizations and determine which ones best suit your organization Formulate... View Details
- 09 Feb 2024
- HBS Case
Slim Chance: Drugs Will Reshape the Weight Loss Industry, But Habit Change Might Be Elusive
what may at first blush appear to be an easier fix: new drugs such as Ozempic, Wegovy, and Mounjaro, says Harvard Business School Professor Regina E. Herzlinger, who has studied the American health care... View Details
- September 2014
- Article
Defining the Value of Proton Therapy Using Time-Driven Activity-Based Costing
By: N.G. Thaker, A.B. Guzman, Thomas W. Feeley, T.M. Jones, J.R. Incalcaterra, C. Kolom, S.J. Frank, L.S. Tatum, Ronald S. Walters, Scott B. Cantor, D.I. Rosenthal, A.S. Garden, G.B. Gunn, C.D. Fuller and M.B. Palmer
Technological innovations in radiation therapy (RT) have rapidly improved the quality of care for patients with head and neck cancer. Intensity-modulated proton therapy (MPT) holds promise of further improving outcomes compared with the current photon-based technique... View Details
Keywords: Time-Driven Activity-Based Costing; Health Care and Treatment; Technological Innovation; Activity Based Costing and Management
Thaker, N.G., A.B. Guzman, Thomas W. Feeley, T.M. Jones, J.R. Incalcaterra, C. Kolom, S.J. Frank, L.S. Tatum, Ronald S. Walters, Scott B. Cantor, D.I. Rosenthal, A.S. Garden, G.B. Gunn, C.D. Fuller, and M.B. Palmer. "Defining the Value of Proton Therapy Using Time-Driven Activity-Based Costing." Oncology Payers, no. 1 (September 2014): 22–28.
- 05 Sep 2017
- News
Bargaining With Cancer Patients About Treatment
- Web
Measure Outcomes & Cost for Every Patient - Institute For Strategy And Competitiveness
HBS ISC Health Care Health Care Value-Based Health View Details
- 13 Apr 2017
- News
What Precision Medicine Can Learn from the NFL
- 20 Jul 2021
- News
Rewriting the Social Contract
Innovating in Healthcare: Creating Breakthrough Services, Products, and Business Models
Innovating in Healthcare offers effective approaches for designing, reworking, and implementing innovative healthcare services, products, and business models. It will help anyone working in healthcare service or product development, from hospitals to... View Details
- 02 Sep 2014
- First Look
First Look: September 2
legacy labor and health care costs-is seriously incomplete and that GM's share collapsed for many of the same reasons that many of the other highly successful American firms of the 50s, 60s, and 70s were... View Details
Keywords: Sean Silverthorne
- 22 Sep 2016
- News
The Road to Successful Bundled Payment Risk
- March 2018 (Revised January 2019)
- Case
Gilead Mexico
By: Michael Chu and V. Kasturi Rangan
With a breakthrough cure for Hepatitis C listing in the U.S. at $1,000/pill, Gilead must now solve the issue of making it available to patients across the world, much as it did for its blockbuster HIV/AIDS antiretrovirals. For Erik Musalem, the new general manager of... View Details
Chu, Michael, and V. Kasturi Rangan. "Gilead Mexico." Harvard Business School Case 318-111, March 2018. (Revised January 2019.)
- Article
The Economic Consequences of Hospital Admissions
By: Carlos Dobkin, Amy Finkelstein, Raymond Kluender and Matthew Notowidigdo
We use an event study approach to examine the economic consequences of hospital admissions for adults in two datasets: survey data from the Health and Retirement Study, and hospitalization data linked to credit reports. For non-elderly adults with health insurance,... View Details
Keywords: Personal Finance; Borrowing and Debt; Insurance; Insolvency and Bankruptcy; Health Care and Treatment
Dobkin, Carlos, Amy Finkelstein, Raymond Kluender, and Matthew Notowidigdo. "The Economic Consequences of Hospital Admissions." American Economic Review 108, no. 2 (February 2018): 308–352.
- Article
Extracorporeal Membrane Oxygenation Appropriateness: An Interdisciplinary Consensus-Based Approach
By: Robert S. Kaplan, Michael Nurok, Jonathan Warsh, Todd Griner, Mayumi Kharabi, Joseph Castongia, Cali Overbeck, Lisa Krueger, Bernice Coleman, Danny Ramzy, Joshua Chung, Alice Chan, Eric Ley, Sindhu Kubendran, Neil Parrish, Zhe Yu, Michael Landberg, Stuart Finder, Bradley T. Rosen, Harry Sax and Francisco Arabia
We describe a quality improvement initiative aimed at achieving interdisciplinary consensus about the appropriate delivery of extracorporeal membrane oxygenation (ECMO). Interdisciplinary rounds were implemented for all patients on ECMO and addressed whether care was... View Details
Kaplan, Robert S., Michael Nurok, Jonathan Warsh, Todd Griner, Mayumi Kharabi, Joseph Castongia, Cali Overbeck, Lisa Krueger, Bernice Coleman, Danny Ramzy, Joshua Chung, Alice Chan, Eric Ley, Sindhu Kubendran, Neil Parrish, Zhe Yu, Michael Landberg, Stuart Finder, Bradley T. Rosen, Harry Sax, and Francisco Arabia. "Extracorporeal Membrane Oxygenation Appropriateness: An Interdisciplinary Consensus-Based Approach." Anesthesia & Analgesia 128, no. 3 (March 2019).
- 06 Nov 2013
- News
Six Ways to Save Obamacare
- 21 Apr 2009
- First Look
First Look: April 21, 2009
distinguishing between direct and complementary spillovers, we examine (1) the extent to which a hospital's specialization in areas related to cardiovascular care directly impacts performance in cardiovascular View Details
Keywords: Martha Lagace
- 08 Jun 2020
- News
Tenants and Investors Will Be Looking for Healthy Buildings
- Article
Understanding Psychological Safety in Healthcare and Education Organizations: A Comparative Perspective
By: Amy C. Edmondson, Monica Higgins, Sara J. Singer and Jennie Weiner
Psychological safety plays a vital role in helping people overcome barriers to learning and change in interpersonally challenging work environments. This article focuses on two such contexts—health care and education. The authors theorize differences in psychological... View Details
Edmondson, Amy C., Monica Higgins, Sara J. Singer, and Jennie Weiner. "Understanding Psychological Safety in Healthcare and Education Organizations: A Comparative Perspective." Special Issue on the Role of Psychological Safety in Human Development. Research in Human Development 13, no. 1 (2016): 65–83.
- May 2002 (Revised October 2005)
- Case
Marketing Antidepressants: Prozac and Paxil
By: Youngme E. Moon and Kerry Herman
Describes the marketing of Prozac and Paxil, two of the best-selling mental health drugs in history. Set in 2001, several months before the expiration of Prozac's patent, Eli Lilly (Prozac's manufacturer) and GlaxoSmithKline (Paxil's manufacturer) must decide how to... View Details
Keywords: Patents; Product Positioning; Competition; Ethics; Value; Health Care and Treatment; Brands and Branding; Pharmaceutical Industry; United States
Moon, Youngme E., and Kerry Herman. "Marketing Antidepressants: Prozac and Paxil." Harvard Business School Case 502-055, May 2002. (Revised October 2005.)